In a patient with psoriatic arthritis who stopped etanercept due to elevated transaminases and has good skin response but persistent joint pain on ixekizumab (Taltz), what alternative treatment options are recommended?

Switch to an Alternative IL-17 Inhibitor or Consider IL-23 Inhibitor, JAK Inhibitor, or TNF Inhibitor with Better Hepatic Safety Profile

Given persistent joint pain despite good skin response on ixekizumab (Taltz), you should switch to a different biologic class—specifically consider an IL-23 inhibitor (guselkumab, risankizumab) or a JAK inhibitor (upadacitinib, tofacitinib), while avoiding etanercept due to the prior transaminase elevation. 1

Treatment Algorithm Based on Current Guidelines

First-Line Switch Options (in order of preference):

1. IL-23 Inhibitors (Preferred for this scenario)

• Guselkumab or risankizumab are strongly recommended and will maintain excellent skin control while addressing the inadequate joint response 1, 2
• These agents have demonstrated efficacy across all PsA domains including peripheral arthritis
• No significant hepatotoxicity concerns compared to TNF inhibitors
• The 2024 EULAR guidelines support switching within or between biologic classes when there is inadequate response 1

2. JAK Inhibitors (Strong alternative)

• Upadacitinib or tofacitinib are recommended when bDMARDs show inadequate response 1
• The 2024 EULAR guidelines specifically state: "In patients with peripheral arthritis and an inadequate response to at least one bDMARD...a JAKi may be considered, taking safety considerations into account" 1
• JAK inhibitors have shown efficacy for both joint and skin manifestations 2
• Important caveat: Monitor for cardiovascular risk factors, thrombosis risk, and malignancy history given FDA safety warnings with this class

3. Alternative TNF Inhibitor (with caution)

• Consider adalimumab or infliximab rather than returning to etanercept
• The hepatotoxicity profile varies among TNF inhibitors—etanercept may have had idiosyncratic hepatotoxicity in this patient
• Close monitoring of liver enzymes required (baseline, then monthly for 3 months, then quarterly)
• Less preferred given prior TNF inhibitor failure with hepatotoxicity

Why Not Continue Ixekizumab?

The FDA label for Taltz demonstrates that approximately 53-58% of patients achieve ACR20 response, but your patient has inadequate joint pain relief despite good skin response 3. This represents a partial response requiring treatment optimization. The 2024 EULAR guidelines explicitly recommend switching when there is inadequate response to a bDMARD 1.

Critical Considerations for This Patient:

Hepatic Safety Priority:

• Avoid etanercept permanently given the documented transaminase elevation
• Check baseline AST/ALT before starting any new agent
• IL-23 inhibitors and IL-17 inhibitors (other than ixekizumab in this case) have favorable hepatic safety profiles
• JAK inhibitors require liver function monitoring but are generally well-tolerated

Addressing the Inadequate Joint Response:

• The patient's good skin response but poor joint response on ixekizumab suggests differential tissue-specific drug efficacy
• IL-23 inhibitors may provide better joint efficacy while maintaining skin control 2, 4
• Consider adding methotrexate if not contraindicated by the prior liver enzyme elevation—though this requires careful assessment of whether methotrexate contributed to the original transaminase elevation with etanercept

Disease Activity Assessment:

• Document specific joint counts, enthesitis, dactylitis presence
• Assess for axial involvement which may influence drug selection
• If predominantly axial disease: IL-17A inhibitors, TNF inhibitors, or JAK inhibitors are preferred over IL-23 inhibitors 1

Practical Implementation:

1. Obtain baseline labs: CBC, CMP including AST/ALT, hepatitis panel if not recently done
2. Switch directly to the new agent (no washout period typically needed from ixekizumab)
3. First choice: IL-23 inhibitor (guselkumab 100mg at weeks 0,4, then every 8 weeks; or risankizumab 150mg at weeks 0,4, then every 12 weeks)
4. Monitor response at 12-16 weeks with formal joint counts and patient-reported outcomes
5. If inadequate response persists: Consider JAK inhibitor or combination therapy with a csDMARD if appropriate

Common Pitfalls to Avoid:

• Don't assume all TNF inhibitors will cause hepatotoxicity—the reaction may have been drug-specific to etanercept
• Don't continue ixekizumab indefinitely with inadequate joint response hoping for delayed effect—24 weeks is sufficient to assess efficacy 3
• Don't overlook concomitant methotrexate as a potential contributor to the original transaminase elevation
• Don't forget to assess for fibromyalgia or mechanical pain that may coexist and won't respond to biologics

The GRAPPA 2021 guidelines strongly recommend IL-23 inhibitors, IL-17 inhibitors, and JAK inhibitors for peripheral arthritis, with selection based on prior treatment response and safety profile 2. Given this patient's specific history, IL-23 inhibition represents the optimal next step to maintain skin control while improving joint outcomes.